NDAORALGRANULES, EXTENDED RELEASE
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
ASPRUZYO SPRINKLE (ranolazine) by Piramal Pharma is cytochrome p450 3a inhibitors [moa]. Approved for coronary artery disease, angina, myocardial ischemia. First approved in 2022.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASPRUZYO SPRINKLE is an extended-release oral granule formulation of ranolazine, a cytochrome P450 3A inhibitor approved in February 2022. It is indicated for coronary artery disease, angina, and myocardial ischemia, with emerging evidence in heart failure, arrhythmias, and neuromuscular disorders. The drug works by modulating cardiac metabolism and ion channel activity to reduce ischemic symptoms without affecting heart rate or blood pressure.
$0.139BPart D
Peak11.7 years to LOEEarly-peak product with minimal formulary penetration (527 Part D claims in 2023) suggests significant growth opportunity for commercial teams to expand prescriber awareness and patient access.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Anti-anginal
Indications (3)
Worked on ASPRUZYO SPRINKLE at Piramal Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.